A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, and the Fred Hutchinson Cancer Center have identified PTGES3, known as the third prostaglandin E synthase protein, as an unexpected regulator of the androgen receptor.